israeli life science industry catalog
TRANSCRIPT
Government of Israel
Economic Missionto the West Coast
Israeli Life Science Industry CatalogBio International Convention 2016
Israeli Life Science Industry: A Source of InnovationIsraeli Pavilion Booth 2205, June 6-9, 2016
1 | P a g e
Israel: A Powerhouse of Opportunities
Over the last decade, Israel has introduced a wealth of
groundbreaking and valuable innovations in life sciences. Israel’s
life sciences sector is supported by a strong foundation of
academic excellence, including some of the world’s leading
research institutes, renowned R&D facilities and cutting-edge
medical centers. Bolstered by a highly skilled workforce, a
flourishing high-tech environment, and an entrepreneurial spirit,
Israeli companies have been joined by leading multinationals in
making Israel a recognized force in the industry worldwide. Global
giants, including Johnson & Johnson, Perrigo, GE Healthcare,
Phillips Medical, Abbott Laboratories, Merck Serono, Roche,
Takeda, Novartis, Monsanto , together with local companies such
as Teva - itself a multinational company - Given Imaging,
InSightec, Medinol and others have been continuously developing
and marketing life-changing medical breakthroughs and
innovations.
Prior to 1996, Israel was home to 186 life sciences companies. By
2015, this number had passed 1,300. With some 98 new
companies formed each year, 66% of all life sciences companies
operating in Israel today were established during the last ten
years. In a relatively short period of time, an impressive 34% of
these companies have already begun to generate revenue,
demonstrating that Israel has crossed the threshold from an
attractive start-up arena to a source of advanced, commercially
viable and promising businesses. The bridge connecting excellent
science to revenue-generating companies has been established.
As proof of the industry’s development, in 2014 life sciences
exports reached $8.5 billion, an increase of 10% over 2010. A rich
pipeline of seed companies promises to perpetuate current
growth.
Source: Invest in Israel & IATI
Why Israel?
Over 1,300 life sciences companies
Over 1/3 of LS start-ups already generate revenue
Source of numerous blockbuster drugs such as Copaxone and Rebif, generating over $5B in annual sales
Third in the world in innovation [World Economic Forum (WEF) 2015-16]
Life Sciences represent about 50% of Israeli civilian research activities (IATI 2015 report)
Pioneers in stem cell research and therapeutics
Extensive international R&D and commercial partnerships
World-renowned academic research institutes such as the Technion and the Weizmann Institute
Unique financing tools and incubator frameworks for start-ups
1.5% of the worldwide registered patents between 2010-2013 were Israeli (Central Bureau of Statistics)
2 | P a g e
Israel’s Competitive Edge Academia and Research Approximately 50% of all academic research funding in Israel is in the field of
life sciences, and institutions such as the Hebrew University of Jerusalem, Tel
Aviv University, Ben Gurion University of the Negev, the Technion - Israel
Institute of Technology and the Weizmann Institute of Science have played
dominant roles in advancing biotech R&D. In fact, over the past five years, the
Weizmann Institute was ranked twice as the top international academic
institution in the world for scientists to conduct research in life sciences. This
stems from impressive levels of R&D funding and highly skilled and creative
manpower, which continues to generate new patents in the field.
Cluster Effect
Many of Israel’s achievements in the life sciences sector stem from the fact
that over 90% of the population resides within two hours driving time of each
other and within close proximity to seven major universities and industrial
clusters. This cluster effect creates economies of scale, and allows for better
information sharing and synergies between the companies.
Entrepreneurial Spirit and Ingenuity
The exceptional volume of life science start-ups and patents attests to the
entrepreneurial and risk-taking climate in Israel. Israeli researchers and
entrepreneurs overcome technological barriers and solve development
problems within a short period of time and at a fraction of the cost of some of
their larger and more affluent competitors overseas.
Acquisitions of Israeli Life Sciences Companies 2005-2014 Since 2005, 62 Israeli life sciences companies have been acquired, whereby
the aggregate sum of these acquisitions was $7.7 billion excluding royalties.
Between 2013-2014 Israeli life sciences companies were acquired for almost
$2.9 billion (IATI report 2015).
Rapid Research to Financial Return
The last few years have witnessed several
significant Israeli life sciences “exit” transactions
with investors realizing impressive returns via IPOs,
mergers and acquisitions. Close to 60 life science
companies went public on the Tel Aviv Stock
Exchange (TASE) in recent years, among them
BiolineRx, Biondvax, Brainsway, Intec, Mazor,
Prolor, Pluristem, Hadasit Bio Holdings and Nasvax,
and approximately 15 Israeli companies have gone
public on foreign exchanges, mainly in the US. Source: Invest in Israel
3 | P a g e
Meet the Sponsoring Organizations
The sponsoring organizations of the Israeli delegation provide a full array of support and
services to nurture the development of industry and innovation:
The Israel Innovation Authority (formerly the Office of the
Chief Scientist & MATIMOP) is the main authority for
governmental support of technological innovation. The
Authority is Israel's central agency to manage the country’s
resource of innovation and is the Ministry of Economy &
Industry's operational arm in the arena of technological
innovation. The goal of the Authority is to provide
professional support and infrastructure to government
efforts to encourage and promote technological innovation,
complementing the major role that Israel already plays in the
global high-tech sector.
The Israel Advanced Technology Industries (IATI) is Israel’s
largest umbrella organization for companies, organizations,
and individuals in the high tech and life science sectors. In a
country like Israel where innovation is a national mindset,
IATI’s mission is to strengthen the Israeli high tech and life
science industries across the whole value chain and create
global, technological and innovational leadership.
The US-Israel Science and Technology Foundation supports
programs to create a seamless infrastructure for industry,
academia and government for the mutual benefit for the
economies of the US and Israel.
The Foreign Trade Administration at the Ministry of
Economy is responsible for managing and directing the
international trade policy of the State of Israel. The main
fields of activity include activities for the promotion of trade
and export, initiating and maintaining trade agreements for
the improvement of Israel’s trade conditions, attracting and
encouraging foreign investments and creating strategic
cooperation with foreign companies.
4 | P a g e
Meet the 2016 Bio Israeli Delegation
On behalf of the organizers and partners, we would like to introduce you to the 2016 Bio
Israeli Delegation. Twenty remarkable companies are attending, spanning the spectrum of
Israel’s vigorous life science community, from innovative start-ups to established companies.
Please take the time to explore their innovative solutions which you can find in this catalog.
We hope you will take the time to schedule a meeting with some of these companies and
see for yourself why Israel is driving innovation in the life sciences industry. You can visit the
Israel national pavilion at Booth 2205.
Additionally, most of the Israeli companies are participating in the Bio Business Forum
one-on-one partnering service, and you can find them in the online system at:
http://convention.bio.org/partner/
5 | P a g e
Company Name Page
BMR Solutions 7
BrainMARC 8
BrainStorm Cell Therapeutics
9
Can-Fite BioPharma Ltd. 10
ChroniSense Medical 11
Compugen Ltd. 12
DALI Medical Devices 13
Immune System Key 14
Kadimastem 15
Israeli Company Profiles
6 | P a g e
Mybiotics 16
NovellusDx 17
Nucleix 18
Nurami 19
Optical Imaging 20
Oramed 21
PamBio 22
PolyPid 23
Raziel Therapeutics 24
Taliaz Diagnostics 25
VBL Therapeutics 26
7 | P a g e
Company Profile:
BMR Solutions is a privately held Israeli
biopharmaceutical startup company with a
pipeline of small molecule drugs in late pre-
clinical stages, addressing age related diseases
and cancer supportive care in elderly patients.
Based on the proprietary discovery of the
BMRH platform, we do endogenous
stimulation of adult stem cells. Our objective
is to develop and commercialize BMRH stem
cells modulators, for improvement of self-
regenerative capacity of the body.
Technology Description:
Our drugs were discovered in animal source as
a part of four decades of research aimed at
investigation of radio-protective mechanisms
existing in animals and discovery of drugs which cause bone marrow recovery following
deadly irradiation. During this screening research one of the vertebrate animal species was
found to be extremely radio-resistant, about 100 - fold more resistant than humans. Specific
molecules from that animal, which are responsible for stimulation of adult stem cells (stem
cells modulators) have been discovered, characterized and synthetically produced. These
molecules augment recovery of bone marrow and blood and, therefore, induce survival and
recovery of the whole organism after high doses of chemotherapy, irradiation and after age
related damages.
BMR Solutions revealed the importance and the clinical relevance of BMRH family of
synthetic stem cell modulators in thousands of animals in several disease and aging models.
We created a broad pipeline addressing various clinical needs. Our business model includes
collaborations surrounding particular drug candidates for development, strategic
partnership and commercialization.
Company Name: BMR Solutions
Contact Details
Address: 49 Sokolov st, Herzeliya, ISRAEL
Phone: 972-54-5696682
Fax: 972-3-5492874
Email: [email protected]
Website: www.bmrsolutions.co.il
Exhibition Representatives
Name: Ronen Kahana
E-mail: [email protected]
Category: Biopharmaceutical Company
8 | P a g e
Company Profile:
BrainMARC has developed a breakthrough
mobile health platform for monitoring mental
activity. Its’ easy-to-use tool derives proven
and robust biomarkers sampled from two (dry)
EEG electrodes. BrainMARC’s biomarkers are
applicable to a wide spectrum of
neuropsychiatric syndromes where they can
enhance therapeutic protocols, predict clinical
dynamics, and promote general wellness. They
are also suitable for non-medical and research
applications.
Technology Description:
BrainMARC’s platform is based on advanced
analysis technology, providing precise and
easy-to-generate electrophysiological markers for tracking neuropsychological status. The
process is significantly easier than existing EEG-based technologies because only a minimal
number of electrodes is needed (Shahaf and Pratt. 2013, Shahaf et al., 2015) and the target
markers can be extracted from a very short sample. In addition, emotion parameters can be
detected even when the user is active.
BrainMARC's Mental Health monitor is a wearable device for continuous use during daytime
routines. For example, a child with ADHD can wear the device while doing homework to
support effective task planning and performance. The device can also significantly enhance
the effectiveness of cognitive behavioral therapy (CBT) for mental health disorders such as
anxiety, depression, etc. Clinical studies have also demonstrated its potential to dramatically
improve post-stroke rehabilitation treatments.
BrainMARC's Mental Health prediction technology is based on the same wearable device.
However, it is designed to be used on a daily basis for a short (1-5 minute) EEG
measurement session in order to provide an objective neurophysiological measure of the
user’s current condition as well as an indication of immanent clinical dynamics. Used in
conjunction with a mobile app, it can, for example, predict the attention level of an ADHD
subject over the next few hours; the probability of a migraine attack within the next 1-2
days; or, in the case of depression, the efficacy of a specific treatment as well as the
potential for deterioration over the coming weeks.
Company Name: BrainMARC Ltd.
Contact Details
Address: Beit Hermon, Yokneam Illit,
P.O. Box 128, 20692, Israel
Phone: +972-4-666-0677
Fax: +972-4-643-2998
Email: [email protected]
Website: http://brainmarc.com/
Exhibition Representative
Name: Dr. Yael Rozen
E-mail: [email protected]
Category: Digital health
9 | P a g e
Company Profile:
Brainstorm Cell Therapeutics (Nasdaq: BCLI) is
a biotechnology company developing novel
adult stem cell therapies for debilitating
neurodegenerative disorders such as
Amyotrophic Lateral Sclerosis (ALS) and
Multiple Sclerosis among others. These
diseases for the most part have no or limited
treatment options and as such represent
unmet medical needs. We believe that
NurOwn®, our proprietary process for the
propagation of Mesenchymal Stem Cells and
their differentiation into neurotrophic factor
secreting cells and their transplantation at, or
near, the site of damage, offers the hope of
more effectively treating neurodegenerative
diseases.
NurOwn® is in clinical development for the
treatment of ALS. It has been granted Fast
Track designation by the FDA for this indication, and has been granted Orphan Status in both
the United States and in Europe. Brainstorm has completed two clinical trials of NurOwn® in
patients with ALS in Israel. The results of both studies, recently published in JAMA Neurology
(January 2016), showed the treatment was safe and well tolerated and provided indications
of possible clinical benefits on both the ALS Functional Rating Score (ALSFRS-R) and Forced
Vital Capacity (FVC).
Brainstorm is completing a double blind placebo controlled Phase II clinical trial for ALS
patients at three leading US medical centres: Mass. General and UMass hospitals in Boston
and at the Mayo Clinic in Rochester (MN). Additionally, a multi-dose study of NurOwn® for
ALS in Israel is scheduled for 2016. An additional Phase I/II clinical study for other
neurological disorders is also in preparation.
Technology Description:
Bone marrow cells are harvested from the
patient, and Mesenchymal Stromal stem
cells (MSC) are isolated and expanded in
culture. Using the company's core cell
differentiation technology, the MSC are
then induced to differentiate into MSC-NTF
cells (Mesenchymal Stromal Cells-secreting
Neurotrophic Factor) and transplanted back
into the patient at or near the site of
damage.
Company Name: Brainstorm Cell Therapeutics Ltd. Technology Sector: Biotechnology / Cell Therapy / Regenerative Medicine Company Stage: Clinical stage Traded on NASAQ: BCLI Contact Details 12 Bazel Street POB 10019 Kiryat Aryeh Petach Tikva, Israel 4900101 Phone: +972-3-9236384 Fax: +972-3-9236385 Website: www.brainstorm-cell.com Representative Name: Chaim Lebovits President & CEO E-mail: [email protected]
10 | P a g e
Company Profile:
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is
an advanced clinical stage drug development
company with 3 small molecule drug candidates
in its pipeline for the treatment of cancer,
inflammatory diseases, and sexual dysfunction.
Technology Description:
Can-Fite’s platform technology is based on the
finding that the Gi protein-coupled A3
adenosine receptor (A3AR) is over-expressed in
inflammatory and cancer cells. The Company’s
proprietary compounds target and bind with
A3AR and induce specific cell death of cancer
and inflammatory cells. This creates a targeted
anti-cancer and anti-inflammatory effect, while
leaving normal cells unharmed. A3AR is also a
biological predictive marker which helps to
identify individual patients' responsiveness to the Company’s drugs.
CF101 – Arthritis & Psoriasis Ready to Enter Phase III Can-Fite’s 12-week Phase IIb study of
CF101 for the treatment of rheumatoid arthritis included 79 patients. The data showed
CF101 met all primary efficacy endpoints with statistically significant superiority over
placebo in reducing signs and symptoms of rheumatoid arthritis as compared to the placebo.
Psoriasis Phase II/III Study Showed Positive Data, with over 300 patients with moderate to
severe psoriasis suggest CF101 as a potential first-line systemic therapy. Although the study
did not meet its primary endpoint of efficacy at week 12, it showed a statistically significant
and cumulative improvement in efficacy during weeks 16-32. Can-Fite plans to initiate its
Phase III trials in 2016 for both indications.
CF102 - Cancer Drug in Phase II with Fast Track & Orphan Drug Designations The U.S. FDA
granted Can-Fite Fast Track Designation for CF102 as a second line treatment for HCC in
patients who have previously received Nexavar (sorafenib). CF102 has Orphan Drug
Designation in both the U.S. and EU for the treatment of HCC, the most common type of
liver cancer. Can-Fite is currently conducting a Phase II study of CF102 for the treatment of
advanced HCC which is expected to have 78 patients enrolled in the U.S., Europe and Israel.
The drug is also developed for the NASH indication with a Phase II underway.
CF602 - Sexual Dysfunction Drug May Offer Effective, Safer Alternative In preclinical
studies, subjects treated with CF602 showed a 118% improvement in erectile function
measures as compared to placebo. This result is similar to that achieved by Viagra in
preclinical studies. Can-Fite is conducting a full preclinical program for CF602 in preparation
for filing an IND with the U.S. FDA for the indication of sexual dysfunction and submitting a
Phase I protocol to an IRB in Q4 2016.
Company Name: Can-Fite BioPharma
Contact Details
Address: 10 Bareket st. Kiryat Matalon
Phone: +972-3-9241114
Fax: +972-3-9249378
Email: [email protected]
Website: www.canfite.com
Exhibition Representatives
Name: Dr. Sari Fishman
E-mail: [email protected]
Category:
Cancer, Autoimmune & Liver Diseases,
Sexual Dysfunction
11 | P a g e
Company Profile:
ChroniSense Medical is a young startup
developing wearable health monitoring products
for patient use. ChroniSense is focused on
medical-grade, regulatory cleared standards of
sensing and processing physiological data. Our
products are designed to improve the quality of
life of the chronically ill by reducing dependence
on the clinic and bedside monitors. Our group
brings unique multidisciplinary expertise from
engineering, computer programming,
physiology, psychology, mathematics, and
biostatistics to the R&D process. We are based in
Yokneam Science Park, Israel, and are a member
of the Rainbow Medical Group.
Technology Description:
ChroniSense’s main product platform is a
clinical-quality, wrist-wearable medical device. The device incorporates several
breakthrough technologies in medical sensing, and is currently at an advanced R&D stage,
nearly ready for clinical evaluation. Our device includes multiple ultra-sensitive biosensors,
combined with specialized algorithms for estimation of a range of clinical indices like pulse
and respiration rates, blood pressure, electrocardiogram, oxygen saturation, cardiac output,
and more. The system communicates, via Bluetooth LE, with software on a smartphone or
PC; basic analysis is done on the wrist along with basic alerts; advanced analysis and long-
term data storage are performed on the PC/smartphone platforms, with Internet
communications/storage capability.
Such continuous mobile medical monitoring has the potential to greatly benefit chronic
disease sufferers, not only by detecting acute distress episodes, but by tracking
deterioration or improvement with ongoing treatment. Patients would no longer be
restricted to bed or clinic. Alerts and evaluations can be sent to health care providers in real
time, providing round the clock medical security for those who most need it. No other
product is available for such multi-parameter long-term medical follow-up of chronically ill
patients while allowing an active, normal life.
Company Name: ChroniSense Medical
Contact Details
Address: Hamada Street 2, POB 684,
Yokneam 2069202, Israel
Phone: +972-4-8275103
Fax: +972-4-8275102
Email: [email protected]
Website: www.chronisense.com
Exhibition Representatives
Name: Danny Lange
E-mail: [email protected]
Name: Elliot Sprecher
E-mail: [email protected]
Category: Wearable Medical Devices
12 | P a g e
Company Profile:
Compugen is a therapeutic discovery company
with a unique, broadly applicable, predictive
discovery infrastructure, which is advancing its
therapeutic pipeline consisting mainly of early-
stage immuno-oncology programs, aimed at
harnessing the immune system to eradicate
cancer. The company is headquartered in Israel
with R&D facilities in Israel and South San
Francisco .
Our pipeline is based on novel Compugen-
discovered drug targets, primarily immune
checkpoint candidates that are predicted to
provide cancer immunotherapies addressing
unmet cancer types and patient populations, both as monotherapy and as combination
therapy. The Company is working on several exciting novel immune checkpoint programs,
including CGEN-15029, its highest priority internal mAb program which we plan to advance
towards clinical trials.
CGEN-15001 is our lead program for autoimmune diseases. CGEN-15001 is an Fc fusion
protein that contains the extracellular domain of CGEN-15001T, a novel immune checkpoint
discovered by Compugen. CGEN-15001 was shown to inhibit activation of T-cells and to
restore immune balance and has the potential to address multiple autoimmune disease
indications.
The Company’s second discovery program is focused on targets for antibody drug conjugate
(ADC) therapy. Our lead ADC program, CGEN -15027, has demonstrated high expression
levels in lung, ovarian, and pancreatic tumors and cancer killing activity in-vitro, highlighting
its potential as a target for ADC therapy.
Compugen’s business model is based on selectively entering into collaborations for its novel
target candidates and drug product candidates at various stages of research and
development under revenue-sharing agreements. We are currently developing antibody-
based cancer immunotherapies in collaboration with Bayer Healthcare (CGEN-15001T and
CGEN-15022) and have established a joint venture with Merck Serono, Neviah Genomics,
focused on the discovery and development of novel biomarkers for drug toxicity.
Company Name: Compugen Ltd.
Contact Details
Address: 26 Harokmim Street,
Building D Holon 5885800, Israel
Phone: +972-3-7658-585
Fax: +972-2 3-7658-555
Email: [email protected]
Website:www.cgen.com
Exhibition Representatives
Name: Tsipi Keren Lehrer
E-mail: [email protected]
13 | P a g e
Company Name: DALI Medical Devices
Contact Details:
6 Nahal Harif St.
P.O. Box 13223
Yavne 8122503, Israel
Phone: +972-8-3730080
Fax: +972-8-8585857
E-mail: [email protected]
Website: www.dalimed.com
Exhibition Representative
Name: David Daily, CEO & Co-Founder
E-mail: [email protected]
Categories
Medical Devices, Drug Delivery Devices
Company Profile:
DALI Medical Devices (DALI) was founded in
2003 by a team with more than 15 years of
experience in developing innovative drug
delivery devices for the pharmaceutical
industry.
DALI has developed a family of innovative
autoinjectors (in collaboration with Elcam Drug
Delivery Devices (E3D)) to improve patient
compliance and contribute to treatment
success. Some of these autoinjectors have
received FDA clearance and some have been
selected by major pharma companies.
Leveraging its expertise, DALI is developing a
proprietary new line of safe, easy autoinjectors:
Innovative Safe Auto-Needles (SANs) address unmet needs we identified in the growing
injectable drug-delivery arena.
DALI seeks pharmaceutical, financial, and other strategic partners to bring our unique SANs
to market.
The Technology:
The proprietary SAN product family has been designed for improved patient compliance and
adherence to treatment: All SANs reduce needle phobia, anxiety and pain perception by
hiding the needle, ensuring consistent needle penetration depth and angle, preventing
needlestick injuries, and allowing for user-controlled injection speed for increased comfort.
The unique SANs can be customized for use with all types of syringes, vials and cartridges.
Pipeline technologies: (1) A bolus / large volume injection; and (2) A novel injector for
minimally invasive delivery of therapeutics to the posterior eye (Cooperation with Sheba
Medical Center, Israel).
14 | P a g e
Company Profile:
ISK is a privately held company, engaged in
discovery and development of innovative
treatments for malignant and autoimmune
diseases with strong unmet needs. Its assets
are based on novel human secreted peptides,
which were discovered by the founders.
Technology Description:
ISK’s lead compound is Nerofe. Nerofe was
granted by the FDA with orphan drug status
for AML treatment.
ISK Ltd has completed phase I clinical trial with
Nerofe in cancer patients with progressive
disease. Nerofe is highly safe in humans – no
toxic effects were seen during the trial. Nerofe
is stable in the human blood.
Nerofe is the first highly safe anti-cancer agent
that affects all 3 biological processes that affect cancer progression: Angiogenesis, Cancer
Immunotherapy and Cancer cells proliferation.
In phase I we have clearly seen:
1. Induction of strong anti-angiogenic effect.
2. Activation of anti-cancer immune response.
3. In vitro experiments show that Nerofe has direct strong inhibitory effect on cancer cell
proliferation.
Nerofe's mode of action is through ER-stress mediated by a strong induction of BIP as seen
in-vitro, in-vivo and in the human trial. BIP serum levels change after only two weeks of
Nerofe treatment can help predict the success of the treatment.
We have developed a novel marker whose presence in patient’s biopsy can predict success
of treatment with Nerofe. Patients whose tumor biopsy was positive for the marker stayed
in the trial for 6 month or longer with a Stable Disease.
The company’s main interest is to treat AML, pancreatic and TN breast cancer patients.
Company Name: Immune System Key
LTD.
Contact Details
Address: Hava'ad Haleumi 21, Jerusalem
91160, Israel
Phone: +972-26751189
Fax: +972-26751179
Email: [email protected]
Website: http://www.immunesk.com/
Exhibition Representative
Name: Joel Ohana
E-mail: [email protected]
Category: Biotechnology/Cancer
15 | P a g e
Company Profile:
Kadimastem (TASE: KDST) develops stem cell
based therapeutics for degenerative diseases
of the nervous system and diabetes. The
company’s technological platform enables the
differentiation of stem cells into a range of
functional human cells, including pancreatic
cells that produce and secrete insulin as well
as neuron-supporting cells of the brain. These
functional cells are used for regenerative
medicine to treat neurodegenerative diseases
and diabetes.
Kadimastem relies on technology that was
initially developed at the Weizmann Institute
in Prof. Michel Revel’s laboratory and which is
now being further developed in the company’s
labs in the Weizmann Science Park, Nes Ziona,
Israel. The company's technologies are
protected by patents and patent applications. Kadimastem specializes in generating
functional human cells from human pluripotent stem cells (hPSC). hPSCs can be expanded
indefinitely, allowing industrial scale production under GMP conditions.
Technology Description:
ALS: Multiple studies have demonstrated that brain supporting cells, mainly astrocytes, play
a crucial role in ALS disease progression. In ALS patients the astrocytes were found to be
malfunctioning and to attack the neurons. Kadimastem’s healthy human astrocytes that are
derived from hPSC will be used to compensate for the malfunctioning cells in ALS patients.
Kadimastem’s therapy will be a frozen shelf product containing cells that when thawed will
be administered directly into the patient’s spinal cord fluid by a standard intrathecal
injection under local anesthesia. Following successful development of the ALS treatment,
the company expects to expand the treatment to additional neurodegenerative indications.
Diabetes: The company's solution is based on stepwise differentiation of hPSC towards
pancreatic islet-like clusters, producing functional insulin (beta cells), glucagon (alpha cells)
and other hormones. Starting from large scale hPSC cultures, Kadimastem's process drives
the cells through several condition changes towards pancreatic endocrine cells. These
functional hormone producing cell aggregates will be encapsulated to prevent immune
rejection and mobility in the patient body, while allowing glucose sensing and insulin
secretion. Kadimastem’s therapy will be a shelf product containing cells that, once thawed,
will be administered subcutaneously (under the skin) by a standard injection under local
anesthesia.
Company Name: Kadimastem Ltd.
Contact Details
Address: 7 Sapir St., Nes Ziona, Israel
Phone: +972-73-7971601
Fax: +972-8-9100698
Email: [email protected]
Website: www.kadimastem.com
Exhibition Representatives
Name: Yossi Ben Yosef, CEO
E-mail: : [email protected]
Category: Biotechnology; Cell Therapy; Stem Cells Neurodegenerative Diseases, ALS; Metabolic Diseases; Diabetes
16 | P a g e
Company Profile:
Mybiotics pharma is a life science startup
company, founded in 2013 in Israel. Mybiotics
develops novel Microbiome Pharmaceuticals.
Based on its proprietary Mycrobe delivery
technology, the company develops bacteria-
based products for treatment of microbiome
related diseases including C. difficle infection
and Antibiotic associated diarrhea prevention.
Technology Description:
Delivery Technology
Mycrobe technology solves one of the major
challenges in the probiotic market today: The
delivery of live and colonizing bacteria to the
digestive tract.
Probiotics grown in Mycrobe technology:
1. Survive the acid conditions of the stomach without being enterically coated
2. Colonize the digestive tract thus inducing a substantial and long-lasting effect on the
digestive bacterial community and whole body health.
Whole microbiome transplantation:
Based on the Mycrobe technology, Mybiotics’ whole microbiome tranplantation consists of a
whole microbiome community compromising 70-90% of healthy donor bacteria grown in
laboratory conditions. This product will replace fecal transplantations (FMTs) that are
currently being used for curing recurrent C. difficle infections and potentially other
microbiome related diseases.
Company Name: Mybiotics
Contact Details
Address: Golda Meir 5, P.O 4061, Ness
Ziona 7414001, Israel
Phone: 972-8-6118286
Fax: 972-9-7770250
Email: [email protected]
Website: www.mybiotix.com
Exhibition Representatives
Name: Didi Daboush
E-mail: : [email protected]
Category:
17 | P a g e
Company Profile:
NovellusDx tailors actionable treatment for
cancer patients. Combining a highly
experienced team, cutting-edge technology,
and a propriety service, NovellusDx generates
an array of live cells expressing patient genes,
and monitors their pathway activity, cross-talk
between genes and response to drugs and
drugs combination. NovellusDx delivers
Functional Annotation for Cancer Treatment
system (FACT).
Acting in the untapped, ~$15B market of
oncology diagnosis, NovellusDx is collaborating
with over a dozen leading medical centers to
deliver evidence-based treatment to each
patient. The FACT system also helps biopharma
companies identify subgroups of cancer patients likely to respond to existing therapies,
stratify patients to enable more efficient trials and isolate new target mutations.
Current Achievements:
International and NY state CLIA certified Lab
Dozens of case studies showing added value to NGS
Collaborations with leading medical centers worldwide such as
Massachusetts General Hospital, Mayo Clinic and MOFFITT
Operational service lab opening mid 2016
IVD product core technology POC
Technology Description:
Overview of the process:
1) Patient mutations are reproduced based on biopsy-derived NGS information (E-
patients)
2) Personalized chip is printed with the patient oncogene. The genes are expressed in live
cells
3) The chip is scanned through a high-content automated microscopy system, and the
oncogenic activity level associated with each specific gene, as well as cross-talk
between genes, is determined
4) The information is presented as a map of the signaling pathways superimposed with all
relevant clinical information
NovellusDx reports the signaling pathway activity in the presence of the patient’s mutated
genes and their response to a battery of drugs and drug combinations.
Company Name: NovellusDx
Contact Details
Address: Jerusalem Bio-Park. Hadassah
Medical Center Campus, Jerusalem
Phone: +972(02)5001100
Fax: +972(02)5477099
Email: [email protected]
Website: www.novellusdx.com
Exhibition Representatives
Name: Dr. Revital Sharivkin
E-mail: : [email protected]
Category: Personalized Medicine
18 | P a g e
Company Profile:
Nucleix Ltd. develops, manufactures and
markets innovative non-invasive molecular
cancer diagnostic tests. Our highly sensitive and
specific tests are based on identification of
subtle changes in methylation patterns. Nucleix
technology is based on a combination of a new
biochemical platform in conjunction with
sophisticated algorithms.
Our first product Bladder EpiCheck® is a urine
test for monitoring of bladder cancer, and
includes a panel of 15 proprietary biomarkers
that are multiplexed in a real-time PCR analysis.
This test has shown 90% sensitivity, 83%
specificity and 97% NPV (based on a cohort of
221 patients that were monitored for
recurrence by Prof. Ilan Leibovitch at Meir
Medical Center in Israel) and it is expected to
reach the market during 2016.
Nucleix pipeline includes diagnostic tests for lung and colorectal cancer detection from
blood samples, using its proprietary and highly innovative technology. Nucleix is backed up
by leading investors including OrbiMed - the world’s largest bio-medical VC funds.
Technology Description:
Methylation of the DNA is a set of ‘switches’ that activate or deactivate specific genes in
order to allow different cell types to perform their role. It is therefore a powerful tool to
distinguish between cell types. Cancer cells show changes in methylation pattern in relation
to healthy cells, and if one could “read” these methylation changes against a large
background of normal signal coming from healthy cells, one would be able to detect the
presence of tumors in body fluids, such as urine and blood. Nucleix technology is based on
our two platforms:
Bioinformatics tool - enabling rapid and systematic discovery and development of
biomarker panels for a wide range of clinical tasks, based on sophisticated
algorithms.
Biochemical tool – a proprietary technology for a simple, low cost clinical assay with
a biochemical sensitivity that is better than 1:150,000 (that is identifying one
methylation change in a background of 150,000 normal molecules).
The above tools enable Nucleix to develop highly sensitive and specific cancer diagnostic
tests as proved by our first product Bladder EpiCheck – a urine test for bladder cancer
detection and monitoring (Bladder EpiCheck is not approved for clinical use)
Company Name: Nucleix Ltd.
Contact Details
Address: 3 Pekeris St. Rehovot 7670203
Israel
Phone: +972-8-9161616
Fax: +972-89166966
Email: [email protected]
Website: www.nucleix.com
Exhibition Representatives
Name: Arnon Horev
E-mail: [email protected]
Category: Cancer Diagnostics
19 | P a g e
Company Profile:
Nurami Medical Ltd. is a medical device
company with a revolutionary, proprietary
nanofiber and sealant technology focused on
the soft tissue repair market, which is worth
$10 billion globally. With its ability to produce
highly flexible, durable and multi-functional
patches that seal undesired leakages and
enhance tissue-regeneration, Nurami Medical
is positioned at the forefront of next-
generation surgery. Nurami's first product is a
dural substitute patch for neurosurgeries.
Nurami is conducting advanced pre-clinical
trials and plans to initiate clinical trials by the
end of 2016.
Technology Description:
Nurami developed ArtiFascia® a revolutionary nanotechnology solution that address a
problem inherent to many current soft tissue reconstruction products. ArtiFascia® is an
innovative porous patch made of synthetic medical-grade biodegradable nanofibers
combined with a special deformable sealant embedded in the patch itself. The nanofibers
promote tissue regeneration whereas the sealant prevents leakage. First product is a Dural
substitute for neurosurgery. Lung surgery, colo-rectal anastomosis are products in
development. Nurami is at advance pre-clinical stage and plans to start first in human trials
for the neurosurgery application by the end of 2016.
Company Name: Nurami Medical LTD
Contact Details
Address: Nazareth, Israel
Phone: +972-54-4487-673
Fax: +972-4-656 4129
Email: [email protected]
Website: Nurami-medical.com
Exhibition Representatives
Name: Dr Amir Bahar
E-mail: : [email protected]
Category:
Regenerative implantable medical
device
20 | P a g e
Company Profile:
Today, Optical Imaging Ltd. (OI) develops,
manufactures and sells its proprietary
breakthrough functional and multi-modal
imaging system into the ophthalmology &
neurology markets. Looking forward, the
company intends to expand applications into
systemic diseases – targeting cardiology and
vascular diseases – a market that is ripe for
an easy-to-use, versatile imaging system for
the diagnosis and management of systemic
diseases. The company’s imaging systems
address multi-billion dollar markets. Optical
Imaging’s vision is to provide clinicians with a
multi-modal, functional, non-invasive retinal
imaging platform to improve diagnosis and treatment monitoring, starting with
ophthalmology and neurology and then expanding the platform to other organs of the body
-- through the eye and directly. Because the eye truly is a window, it can enable the
assessment, diagnosis and management for many systemic diseases: (1) Neurological
diseases, including Alzheimer’s & Multiple Sclerosis; (2) Blinding Conditions like Diabetic
Retinopathy, AMD & Glaucoma; (3) Cardiovascular diseases and risk assessment of stroke.
The founder & chief scientist, Prof. Amiram Grinvald from the Weizmann institute, won the
Dan David Prize for the innovative research & development of optical imaging.
Technology Description:
Optical Imaging’s multi-modal, functional, non-invasive retinal imaging system can provide
the clinician with missing information of tissue/organ functional parameters by means of
comparative processing of consecutive images taken in a form of a short movie. The unique
nature of this technology is based on its proprietary data acquisition protocols and image
processing algorithms, enabling the comparative analysis of the different information
retrieved from the consecutive images that contain very small optical changes associated
with metabolic processes. Hence, this technology literally enables one to “see the invisible”,
e.g. the movement of red blood cells through blood vessels of the retina, the brain or other
tissue. The technology provides a quantitative functional mapping of four innovative vital
indices: (i) visualization of “invisible capillaries” for diagnostic purposes, follow-up and
enhanced treatment of neovascularization (related to degeneration & cancer diseases); (ii)
Non-invasive and precise quantification of the velocity of blood flow within the capillary bed,
as well as in secondary and tertiary small blood vessels (as related to Atherosclerosis); (iii)
Measuring oxygen saturation non-invasively, serving as a major breakthrough in diagnosis
and topographically directed treatment of retinal, brain and cardiovascular diseases; and (iv)
Imaging of metabolic and electrical activities. Conventional parameters provided by the 60
year-old gold standard can also be measured.
Company Name: Optical Imaging Ltd.
Contact Details
Address: Rehovot, Israel
Phone: +972-8-9463259
Fax: +972-8-9463261
Email: [email protected]
Website: www.opt-imaging.com
Exhibition Representatives
Name: Sagi Reuven
E-mail: : [email protected]
Category: Medical Device
21 | P a g e
Company Profile:
Oramed Pharmaceuticals (NASDAQ: ORMP) has
developed an innovative technology to transform
injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin
capsule, has the potential to better the lives of
millions of diabetics around the world – allowing,
amongst other things, type 2 patients to begin
insulin therapy earlier without fear of needles.
Oramed’s oral insulin is currently in advanced
clinical trials under the US FDA for both type 1
and type 2 diabetes.
In addition to oral insulin, the company’s
proprietary POD™ (Protein Oral Delivery)
technology can be used to orally administer a
number of protein-based therapies, which are
available only via injection.
Technology Description:
Oramed’s POD™ technology has been designed to protect orally delivered proteins from
detrimental enzymatic activity within the gastrointestinal tract and to enhance their
absorption across the intestinal wall.
The active protein is protected within a capsule that features a highly protective coating as
well as specialized protease inhibitors.
Drug availability is further secured by an absorption enhancer that facilitates protein passing
across the intestinal barrier.
Company Name:
Oramed Pharmaceuticals
Contact Details
Address: Hi-Tech Park 2/4 Givat Ram
Jerusalem
US Phone: +1-718-831-2512
Phone: 972-2-566-0001
Fax: 972-2-566-0004
Email: [email protected]
Website: www.oramed.com
Exhibition Representatives
Name: Nadav Kidron
E-mail: : [email protected]
Category: Pharmaceutical
22 | P a g e
Company Profile:
PamBio is an innovative, pre-clinical stage
biotechnology company developing drug
therapy for acute bleeding conditions and
specifically for the treatment of intracranial
hemorrhage (ICH, stroke). There is an unmet
need for a safe and effective treatment for
acute bleeding conditions, with no current
treatment for ICH. ICH accounts for about 10-
15% of all strokes. There are approximately
100,000 new ICH cases per year in the US. The
death rates after an ICH are about 31% at the
first 7 days and 59% at one year, and many
patients who survive are left disabled.
According to the internet stroke center, the
estimated lifetime cost for a new case of ICH is
US$ 123,565. This translates to US$ 8-9 Billion
dollars cost to society to treat ICH new cases
each year.
Technology Description:
Our drug product in development is an inactive recombinant mutant-tPA protein. Its S481A
amino acid substitution renders the protein catalytically inactive but maintains its structure
and ability to interact with major components of the fibrinolytic pathway. This tPA-S481A
therapeutic biomolecule has a dual, anti-fibrinolysis and neuroprotective effect:
A. Blocking of both tPA and uPA fibrinolysis enzymes’ activity, which makes it currently
the only anti-bleeding agent available for treatment in a time-window of beyond 3 hours
B. Limiting tPA and glutamate mediated neurotoxicity and providing neuroprotection,
by blocking the binding of tPA to NMDA receptors
PamBio’s mutant-tPA proposed drug benefits include:
Stabilizing blood clots (in contrast to creating blood clots) and preventing bleeding
Increasing the anti-bleeding treatment time-window to beyond 3 hours
Minimizing blood toxicity in the brain, by preventing bleeding
Preventing NMDA-receptor-mediated excitotoxic neuronal death – a
neuroprotection effect
A high degree of similarity to human protein that minimizes potential
immunogenicity and organ/tissue toxicity
A high target specificity for reduced side effects
A high affinity binding to targets to minimize dose
A unique and safe mechanism of action
A short half-life
Company Name: Pam-Bio Ltd.
Contact Details
Address: P.O. Box 1252,Nazareth Illit
17111, Israel
Phone: +972-4-6098606
Fax: +972-4-6564129
Email: [email protected]
Website:
http://www.ngt3vc.com/pambio-
innovating
Exhibition Representatives
Name: Amos Ofer, PhD, MBA - CEO
E-mail: : [email protected]
Category: Biotechnology and pharma
23 | P a g e
Company Profile:
PolyPid is an emerging clinical stage specialty
pharmaceutical company focused on clinical and
commercial development of products based on a
proprietary platform, PLEX™ (Polymer-Lipid
Encapsulation matriX). It operates in the field of
extended release, local drug delivery where
current local or systemic administration has
limited effect, is too toxic, or both. Our business
model combines both the development of our
proprietary pipeline together with collaboration
with other companies to support the
development of their novel drugs by the PLEX
technology. On our proprietary pipeline arm we
are focused on infection treatment and
prevention, an increasing global health concern,
accounting for 99,000 deaths in the US alone
every year. This way, we mainly target the
Surgical Site Infections (SSIs), the second most
prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative
impact on patients’ clinical outcomes, is the most common reason for unplanned
readmission and therefore poses a significant healthcare system burden. PLEX™ efficacy was
demonstrated clinically in osseous tissues using BonyPid-1000™. BonyPid-1000™ is a PLEX™
based product that contains a powerful antibiotic and it is combined with bone graft
substitute, intended for supporting an antibacterial secured bone healing process in
contaminated sites. BonyPid-1000™ has completed a clinical trial in severe open fractures
indication, demonstrating excellent safety and efficacy results, including 0% infections in the
target fracture and 0% amputations after 6-12 months follow up (vs. average of 25% and 7%,
respectively in historical control group with the same severity and from the same hospital).
BonyPid-1000 is currently in the pivotal trial stage and is expected to gain market approval in
2017.
Technology Description:
The PLEX™ platform is a matrix made of thousands of layers of polymers and lipids that
entrap a therapeutic drug, thus enabling an effective pre-determined, controlled, constant
and considerably prolonged localized drug delivery inside the body.
Demonstrated to fit all drugs sizes and characteristics i.e. many drugs can be used, including small molecules, peptides, proteins and nucleic acids
Prolonged duration - Days >>Weeks >> Months, pre-programmed as needed
Protected drug reservoir - protection from in vivo hydration and enzymatic degradation over the needed extended period
Constant and controlled release rate, pre-programmed as needed
Versatile solutions – multiple drug combinations can be used
No chemical bonds are formed between the drug and the formulation compounds
Administration – pure structures as well as coating of medical devices
Company Name: PolyPid
Contact Details
Address: 18 Hasivim st., Petach-
Tikva, Israel
Phone: +972-747195700
Fax: +972-747195718
Email: [email protected]
Website: www.polypid.com
Exhibition Representatives Name: Amir Weisberg E-mail: [email protected]
Name: Noam Emanuel Email: [email protected] Name: Dan Popovic Email: [email protected] Category: Drug Delivery
24 | P a g e
Company Profile:
Raziel Therapeutics is a clinical-stage
pharmaceutical company developing a
proprietary drug (NCE) that after a single
injection into subcutaneous fat, converts
white adipose tissue (WAT) into
thermogenic, brown-like adipose tissue.
Raziel’s prime-candidate, RZL-012, is a first-
in-class, currently in clinical development
to treat obesity and related disorders.
Raziel launched its clinical trial in the US at
Q4 2015, expecting final data that include
safety and efficacy, by mid of 2016.
Technology Description:
We become fat because we do not burn enough calories, yet consume extra food. Enhanced
thermogenesis (=heat production) can correct this imbalance. Thermogenesis in large
animals is different than that of small rodents and Raziel carefully verified that its drug acts
in small and large mammals as well. Raziel’s novel drug is able to convert energy-storing
white-adipose-tissue (WAT) into energy-burning brown-like adipose tissue, as evident by
histological, cellular and molecular studies. Moreover, the physiological outcome of this
tissue-remodelling is an outstanding local thermogenesis as clearly demonstrated in human-
size pigs. This thermogenesis lasts for several months following a single treatment, with the
ensuing ~30-50% reduction in s.c. fat at the treated site. The molecular target of Raziel
proprietary drug was also identified and is part of Raziel IP.
Company Name: Raziel Therapeutics LTD
Contact Details
Address: Hadassah Ein Kerem Jerusalem
Phone: 972 2 6250907
Fax: 972 2 6250901
Email:[email protected]
Website: Raziel-therapy.com
Exhibition Representatives
Name: Alon Bloomenfeld
E-mail: [email protected]
Category: Pharmaceutical
25 | P a g e
Company Profile:
Taliaz Diagnostics develops genetic and
clinical-based predictive tools through
proprietary machine-learning algorithms to
guide clinicians in prescribing the right
medication for each individual patient.
The company's first tool is designed to
determine the right antidepressant
medication for each individual suffering from
depression. This tool includes a tissue
collection kit, a chip for DNA sequencing of
specific genomic regions, and algorithms
which analyze the unique genetic and clinical
information collected from each patient. The
tool ultimately generates a simple report
which guides the physician to prescribe the
correct treatment.
Technology Description:
Our core technology is based on a proprietary predictive algorithm using the patient's DNA
sequencing to analyze 180 distinct genetic alterations through a simple non-invasive test
which yields results within 24 hours. The tool provides an objective match of the specific
drug with the most efficiency and least adverse effects for the individual patient.
Our diagnostic chip identifies the patient’s relevant genetic variations which together with
selected clinical features are uploaded to the cloud where our in-house big data and
developed machine learning algorithms analyzes the data. The algorithms ultimately predict
the right medication most suited for the individual patient.
Company Name: Taliaz Diagnostics Ltd.
Contact Details
Address: 2 Prof. Yehezkel Kaufmann St.,
Tel Aviv-Yafo, Israel
Phone: +972-(0)53-822-3951
Fax: +972-(0)77-335-2506
Email: [email protected]
Website: www.taliazdiagnostics.com
Exhibition Representatives
Name: Dr. Dekel Taliaz, PhD
E-mail: [email protected]
Category: Diagnostics
26 | P a g e
Company Profile:
VBL Therapeutics [NASDAQ:VBLT] is a late-stage
clinical biopharmaceutical company focused on
developing game-changing, innovative anti-
cancer therapies. Our lead oncology product, VB-
111, is a first-in-class, targeted anti-cancer gene-
therapy agent that is positioned to treat a wide
range of solid tumors. VB-111 is conveniently
administered as an IV infusion once every two
months. It has demonstrated safety in >170
cancer patients and efficacy signals in an `all
comers` Ph1 trial as well as in three tumor-
specific Ph2 studies. The mechanism of VB-111
combines blockade of tumor vasculature with an
anti-tumor immune response. This mechanism
retains activity regardless of baseline tumor
mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is
currently being studied in the GLOBE Ph3 pivotal trial for Recurrent Glioblastoma (rGBM);
the trial is being conducted under an FDA Special Protocol Assessment (SPA), Fast track and
Orphan designation. Based on interactions with the FDA, we believe the current trial, if
successful, will support a Biologics License Application (BLA) in 2018. VB-111 is protected by
an issued composition-of-matter US patent, which extends to 2033, before any extensions.
Technology Description:
VBL’s innovative, proprietary Vascular Targeting System (VTS™) platform technology
enables systemic administration of gene therapy to either destroy or promote angiogenic
blood vessels. VTS is both tissue and condition-specific, allowing for targeted and limited
gene expression in endothelial cells. For oncology applications, the transgene selected is
designed to destroy angiogenic blood vessels that feed solid tumors. For other potential
applications, such as ischemia, a different transgene can be selected that is designed to
promote the development of angiogenic blood vessels. Our Lecinoxoids platform technology
comprises a family of orally-administered small molecules designed to modulate the body’s
inflammatory response. Through inhibition of Toll-like Receptors and monocyte migration,
these safe oral molecules have the potential to treat conditions such as Atherosclerosis,
NASH and renal Fibrosis.
Company Strategy:
VBL has developed a diversified portfolio which includes both gene-therapy biologics and
anti-inflammatory small molecules. As we stay focused on oncology, we intend to pursue
regulatory approval for VB-111 in rGBM and continue development of VB-111 in Ovarian
Cancer. The company is seeking a strategic partner/s that will collaborate with VBL to fully
realize the potential of the VB-111 unique and innovative opportunity for multiple solid
tumors. We seek to out-license our non-oncology assets to support further development
and growth.
Company Name:
VBL Therapeutics [NASDAQ:VBLT]
Contact Details:
6 Jonathan Netanyahu St.
Or Yehuda, 60376 Israel
Email: [email protected]
Website: www.vblrx.com
Exhibition Representatives:
Erez Feige, Ph.D., M.B.A.
VP Business Operations
Eyal Breitbart, Ph.D.
VP Research and Operations
Category: Biopharmaceutical
27 | P a g e
NOTES
28 | P a g e
NOTES
Government of Israel
Economic Missionto the West Coast
www.Innovationisrael.org.il
Israeli Life Science Industry: A Source of InnovationIsraeli Pavilion Booth 2205, June 6-9, 2016